Long-Term Comprehensive Management of Bilateral Limbal Stem Cell Deficiency Secondary to Severe Chemical Burn: 10 Years of Follow-Up

References

• Haring RS, Sheffield ID, Channa R, Canner JK, Schneider EB. Epidemiologic trends of chemical ocular burns in the United States. JAMA Ophthalmol. 2016;134(10):1119–1124. doi:10.1001/jamaophthalmol.2016.2645.
   PubMed Web of Science ®Google Scholar
• Eslani M, Baradaran-Rafii A, Movahedan A, Djalilian AR. The ocular surface chemical burns. J Ophthalmol. 2014;2014:196827. doi:10.1155/2014/196827.
   PubMed Web of Science ®Google Scholar
• Gupta N, Kalaivani M, Tandon R. Comparison of prognostic value of Roper Hall and Dua classification systems in acute ocular burns. Br J Ophthalmol. 2011 Feb;95(2):194–198. doi:10.1136/bjo.2009.173724.
   PubMed Web of Science ®Google Scholar
• Tuft SJ, Shortt AJ. Surgical rehabilitation following severe ocular burns. Eye. 2009;23(10):1966–1971. doi:10.1038/eye.2008.414.
   PubMed Web of Science ®Google Scholar
• Dua HS, King AJ, Joseph A. A new classification of ocular surface burns. Br J Ophthalmol. 2001;85(11):1379–1383. doi:10.1136/bjo.85.11.1379.
   PubMed Web of Science ®Google Scholar
• Deng SX, Kruse F, Gomes JAP, et al. Global consensus on the management of limbal stem cell deficiency. Cornea. 2020;39(10):1291–1302. doi:10.1097/ico.0000000000002358.
   PubMed Web of Science ®Google Scholar
• Iyer G, Srinivasan B, Agarwal S, Agarwal M, Matai H. Surgical management of limbal stem cell deficiency. Asia-Pacific J Ophthalmol. 2020;9(6):512–523. doi:10.1097/apo.0000000000000326.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Mogilishetty G, Skeens HM, et al. Systemic immunosuppression in ocular surface stem cell transplantation: results of a 10-year experience. Cornea. 2012;31(6):655–661. doi:10.1097/ICO.0b013e31823f8b0c.
   PubMed Web of Science ®Google Scholar
• Kuckelkorn R, Schrage N, Keller G, Redbrake C. Emergency treatment of chemical and thermal eye burns. Acta Ophthalmol Scand. 2002 Feb;80(1):4–10. doi:10.1034/j.1600-0420.2002.800102.x.
   PubMedGoogle Scholar
• McCulley JP. Ocular hydrofluoric acid burns: animal model, mechanism of injury and therapy. Trans Am Ophthalmol Soc. 1990;88:649–684.
   PubMedGoogle Scholar
• Soleimani M, Naderan M. Management Strategies of Ocular Chemical Burns: current Perspectives. Clin Ophthalmol. 2020;14:2687–2699. doi:10.2147/opth.S235873.
   PubMed Web of Science ®Google Scholar
• Yu FS, Yin J, Xu K, Huang J. Growth factors and corneal epithelial wound healing. Brain Res Bull. 2010 Feb 15;81(2–3):229–235. doi:10.1016/j.brainresbull.2009.08.024.
   PubMed Web of Science ®Google Scholar
• Higuchi A. Autologous serum and serum components. Invest Ophthalmol Vis Sci. 2018;59(14):DES121–DES129. doi:10.1167/iovs.17-23760.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Forbice E, Braga O, Bova A, Di Salvatore A, Azzolini C. Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies. Biomed Res Int. 2014;2014:826970. doi:10.1155/2014/826970.
   PubMed Web of Science ®Google Scholar
• Hampel U, Klonisch T, Sel S, Schulze U, Paulsen FP. Insulin-like factor 3 promotes wound healing at the ocular surface. Endocrinology. 2013;154(6):2034–2045. doi:10.1210/en.2012-2201.
   PubMed Web of Science ®Google Scholar
• Diaz-Valle D, Burgos-Blasco B, Gegundez-Fernandez JA, et al. Topical insulin for refractory persistent corneal epithelial defects. Eur J Ophthalmol. 2021 Sep;31(5):2280–2286. doi:10.1177/1120672120958307.
   PubMed Web of Science ®Google Scholar
• Wang AL, Weinlander E, Metcalf BM, et al. Use of topical insulin to treat refractory neurotrophic corneal ulcers. Cornea. 2017 Nov;36(11):1426–1428. doi:10.1097/ico.0000000000001297.
   PubMed Web of Science ®Google Scholar
• Watson SL, Secker GA, Daniels JT. The effect of therapeutic human serum drops on corneal stromal wound-healing activity. Curr Eye Res. 2008 Aug;33(8):641–652. doi:10.1080/02713680802254790.
   PubMed Web of Science ®Google Scholar
• Sánchez-Ávila RM, Vázquez N, Chacón M, et al. Fibrin-plasma rich in growth factors membrane for the treatment of a rabbit alkali-burn lesion. Int J Mol Sci. May 25 2021;22(11):5564. doi:10.3390/ijms22115564.
   PubMed Web of Science ®Google Scholar
• Sánchez-Ávila RM, Merayo-Lloves J, Riestra AC, et al. Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders. Medicine (Baltimore). 2018 Apr;97(17):e0242. doi:10.1097/md.0000000000010242.
   PubMed Web of Science ®Google Scholar
• Atallah MR, Palioura S, Perez VL, Amescua G. Limbal stem cell transplantation: current perspectives. Clin Ophthalmol. 2016;10:593–602. doi:10.2147/opth.S83676.
   PubMed Web of Science ®Google Scholar
• Shanbhag SS, Patel CN, Goyal R, Donthineni PR, Singh V, Basu S. Simple limbal epithelial transplantation (SLET): review of indications, surgical technique, mechanism, outcomes, limitations, and impact. Indian J Ophthalmol. 2019 Aug;67(8):1265–1277. doi:10.4103/ijo.IJO_117_19.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, Alcalde I, Merayo-Lloves J, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery. Exp Eye Res. Oct 2013;115:153–161. doi:10.1016/j.exer.2013.07.007.
   PubMed Web of Science ®Google Scholar
• Anitua E, Sanchez M, Merayo-Lloves J, De la Fuente M, Muruzabal F, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-Induced myodifferentiation. Invest Ophthalmol Vis Sci. 2011 Aug 1;52(9):6066–6073. doi:10.1167/iovs.11-7302.
   PubMed Web of Science ®Google Scholar
• Etxebarria J, Sanz-Lázaro S, Hernáez-Moya R, et al. Serum from plasma rich in growth factors regenerates rabbit corneas by promoting cell proliferation, migration, differentiation, adhesion and limbal stemness. Acta Ophthalmol. 2017 Dec;95(8):e693–e705. doi:10.1111/aos.13371.
   PubMed Web of Science ®Google Scholar
• Ibares-Frías L, Gallego-Muñoz P, Orive G, et al. Potential effect of plasma rich in growth factors-endoret in stromal wound healing in additive surgery. Ophthalmic Res. 2020;63(2):203–212. doi:10.1159/000501507.
   PubMed Web of Science ®Google Scholar
• Soifer M, Tovar A, Wang M, et al. A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America. Ocul Surf. Apr 27, 2022;25:40–48. doi:10.1016/j.jtos.2022.04.007.
   PubMed Web of Science ®Google Scholar
• De Aracena Del Cid R M, De Espinosa Escoriaza I M. Subconjunctival application of regenerative factor-rich plasma for the treatment of ocular alkali burns. Eur J Ophthalmol. 2009 Nov-Dec;19(6):909–915. doi:10.1177/112067210901900603.
   PubMed Web of Science ®Google Scholar
• Panda A, Jain M, Vanathi M, Velpandian T, Khokhar S, Dada T. Topical Autologous Platelet-Rich Plasma Eyedrops for Acute Corneal Chemical Injury. Cornea. 2012;31(9):989–993. doi:10.1097/ICO.0b013e3182114661.
   PubMed Web of Science ®Google Scholar
• Movahedan A, Genereux BM, Darvish-Zargar M, Shah KJ, Holland EJ. Long-term management of severe ocular surface injury due to methamphetamine production accidents. Cornea. 2015 Apr;34(4):433–437. doi:10.1097/ico.0000000000000364.
   PubMed Web of Science ®Google Scholar